Organisation paid for research Program year 2021 Source: CMS Open Payments

Upstate Infectious Diseases Associates

Neither a doctor nor a teaching hospital

Research payments

$24,653

25 payments

Through program year 2021, Upstate Infectious Diseases Associates is reported as receiving $24,653 in research payments, across 25 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$3,198	2
2020	Research	$10,046	12
2019	Research	$11,409	11

Breakdown

Who paid Research payments · program years 2019–2021

Gilead Sciences, Inc. $24,653 25 payments

Studies the money was for Research payments · program years 2019–2021

A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults $2,433 1 payment
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults $2,282 1 payment
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults $1,676 1 payment
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults $1,646 1 payment
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults $1,506 1 payment
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults $1,374 1 payment
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults $1,365 1 payment
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults $1,321 1 payment
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults $1,241 1 payment
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults $916 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.